

Innovative Discovery Center



Innovation for Life

We invite you to our open innovation ecosystem.

IDC (Innovative Discovery Center) aims to foster growth towards an 'Open Innovation Center'. Through exchange, collaboration, and convergence of science and technology, IDC strives to advance a future that contributes to human life. Our value grows through community efforts.

We will achieve scientific accomplishments through mutual contributions.



We connect your great inspirations together.

We are driven by the aspiration to serve as catalysts in uniting the extraordinary inspirations that span across the globe. By nurturing a network of open connections among diverse scientific endeavors, our aim is to unveil the hidden treasures of potential, causing them to rise and shimmer upon the tranquil surface of water, evoking a sense of awe and wonder.

IDC is located in Busan, a beautiful coastal Metropolitan city in South Korea.

Let's connect our futures together.

IDC is fostering its own potential by leveraging the "fast drop & go" strategy in developing its pipeline of biosimilars and first-in-class therapeutics. We are actively pursuing collaborations with diverse universities and research institutions to establish an open ecosystem.

We seek to connect and harmonize scientific experiences and inspirations, while fostering an environment of open innovation where the value of new modalities can grow and evolve together. Discover the balance between life and work in Busan. Busan has been chosen as one of the world's best traveling city by National Geographic in 2023.

Our Path to Innovation

First-In-Class Antibody Pipeline




First-in-Class Antibody	PBP1510 Ulenistamab	Pancreatic cancer, Ovarian cancer	Phase 1 clinical trial ongoing
First-in-Class Antibody	PBP1710 Anti-CTHRC1	Solid tumors	Preclinical trial
Bispecific Antibody	IDC001	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific Antibody	IDC002	Pancreatic cancer, Ovarian cancer	Target Identification & Validation
Bispecific Antibody	IDC003	Solid tumors	Target Identification & Validation
Bispecific Antibody	IDC004	Pancreatic cancer, Ovarian cancer	Target Identification & Validation
Bispecific Antibody	IDC005	Solid tumors	Lead Discovery & Optimization
Bispecific Antibody	IDC007	Critical immune disorders	Lead Discovery & Optimization
Bispecific Antibody	IDC008	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific Antibody	IDC009	Pancreatic cancer, Ovarian cancer	Lead Discovery & Optimization
Bispecific Antibody	IDC010	Immune diseases	Lead Discovery & Optimization
Novel Concept Antibody	IDC331	Solid tumors	Target Identification & Validation
	IDC332	Solid tumors	Target Identification & Validation

First-in-Class Antibody PBP1510 (ulenistamab)



- **Development stage** : Phase 1 clinical trial ongoing
- **Indication** : Pancreatic cancer, Ovarian cancer
- **Orphan Drug Designation by FDA, EMA, MFDS**
- **Fast Track Designation by FDA**
- **Target on Pancreatic Cancer**



First-in-Class Antibody PBP1710 (Anti-CTHRC1)

- **Development stage** : Preclinical
- **Indication** : Solid tumors
- **Patent registered in Korea in January 2023**
- **Target on Solid Tumor**

First-in-Class PAUF-detecting Diagnostic Kit

A Powerful Tool for Screening and Detection of pancreatic Cancer

Diagnosis PAUF detection in blood as pancreatic cancer screening

- Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for Pancreatic cancer so far, but it has low specificity.
- The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF.
- In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.



The World's First Biomarker-based Diagnostic Test for Pancreatic Cancer Early Detection
Inviting Clinical Laboratories for LDT partnership



Corporate Headquarters

21 Biopolis Road, #04-24/28
Nucleos South Building, Singapore 138567
Tel: +65 6924 6535
Email: info@prestigebio.com

Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd.
2776-8, Myeongji-dong, Gangseo-gu,
Busan 618-814, South Korea
Tel: +65 51 580 8000
Email: info@prestigebio.com

a member of **CANCER MOONSHOT**

PBPID011023EN



IDC R&D CAMPUSES